ArticleBreast cancer (Tokyo, Japan)2025

IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses.

Yoshiaki Sota et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.